Schalken JA - Search Results

1

Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study.

Govers TM, Hessels D, Vlaeminck-Guillem V, Schmitz-Dräger BJ, Stief CG, Martinez-Ballesteros C, Ferro M, Borque-Fernando A, Rubio-Briones J, Sedelaar JPM, van Criekinge W, Schalken JA. Govers TM, et al. Among authors: schalken ja. Prostate Cancer Prostatic Dis. 2019 Mar;22(1):101-109. doi: 10.1038/s41391-018-0076-3. Epub 2018 Aug 20. Prostate Cancer Prostatic Dis. 2019. PMID: 30127462

2

In vitro proton magnetic resonance spectroscopy of four human prostate cancer cell lines.

Cornel EB, Smits GA, de Ruijter JE, Oosterhof GO, Heerschap A, Debruyne FM, Schalken JA. Cornel EB, et al. Among authors: schalken ja. Prostate. 1995 May;26(5):275-80. doi: 10.1002/pros.2990260508. Prostate. 1995. PMID: 7753713 Free article.

3

Multifocal transitional cell cancer and p53 mutation analysis.

Van Der Poel HG, Hessels D, Van Leenders GJ, Bussemakers MJ, Schalken JA, Witjes JA, Debruyne FM. Van Der Poel HG, et al. Among authors: schalken ja. J Urol. 1998 Jul;160(1):124-5. doi: 10.1097/00005392-199807000-00049. J Urol. 1998. PMID: 9628622 No abstract available.

4

Comparative analysis of p53 mutations in bladder washings and histologic specimens.

Vet JA, Hessels D, Marras SA, van de Kaa CA, van der Poel HG, Michalides RJ, Debruyne FM, Schalken JA. Vet JA, et al. Among authors: schalken ja. Am J Clin Pathol. 1998 Nov;110(5):647-52. doi: 10.1093/ajcp/110.5.647. Am J Clin Pathol. 1998. PMID: 9802351

5

Predictive value of p53 mutations analyzed in bladder washings for progression of high-risk superficial bladder cancer.

Vet JA, Witjes JA, Marras SA, Hessels D, van der Poel HG, Debruyne FM, Schalken JA. Vet JA, et al. Among authors: schalken ja. Clin Cancer Res. 1996 Jun;2(6):1055-61. Clin Cancer Res. 1996. PMID: 9816267

6

DD3(PCA3), a very sensitive and specific marker to detect prostate tumors.

de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, Swinkels DW, Schalken JA. de Kok JB, et al. Among authors: schalken ja. Cancer Res. 2002 May 1;62(9):2695-8. Cancer Res. 2002. PMID: 11980670

7

DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer.

Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, Kiemeney LA, Witjes JA, Schalken JA. Hessels D, et al. Among authors: schalken ja. Eur Urol. 2003 Jul;44(1):8-15; discussion 15-6. doi: 10.1016/s0302-2838(03)00201-x. Eur Urol. 2003. PMID: 12814669

8

New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene.

Schalken JA, Hessels D, Verhaegh G. Schalken JA, et al. Urology. 2003 Nov;62(5 Suppl 1):34-43. doi: 10.1016/s0090-4295(03)00759-3. Urology. 2003. PMID: 14607216 Review.

9

Applicability of biomarkers in the early diagnosis of prostate cancer.

Hessels D, Verhaegh GW, Schalken JA, Witjes JA. Hessels D, et al. Among authors: schalken ja. Expert Rev Mol Diagn. 2004 Jul;4(4):513-26. doi: 10.1586/14737159.4.4.513. Expert Rev Mol Diagn. 2004. PMID: 15225099 Review.

10

Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers.

Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP 3rd, Bono AV, Getzenberg RH, Goebell P, Schmitz-Dräger BJ, Schalken JA, Fradet Y, Marberger M, Messing E, Droller MJ. Lokeshwar VB, et al. Among authors: schalken ja. Urology. 2005 Dec;66(6 Suppl 1):35-63. doi: 10.1016/j.urology.2005.08.064. Urology. 2005. PMID: 16399415

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

420 results

Search Page